The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Real-world safety and efficacy of talquetamab for the treatment of R/R myeloma
Shebli Atrash, MD, Levine Cancer Institute & Atrium Health, Charlotte, NC, shares insight into a real-world analysis exploring the use of talquetamab in patients with heavily pretreated relapsed/refractory (R/R) multiple myeloma (MM), highlighting that the efficacy and toxicity of the agent were consistent with previously published clinical trial data. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
